Blood Purif Continuous Renal Replacement Therapy for a Patient With Severe COVID-19

[tetano]

Blood Purif


. 2020 Jun 11;1-3.
doi: 10.1159/000508062. Online ahead of print.
Continuous Renal Replacement Therapy for a Patient With Severe COVID-19


Daisuke Katagiri ¹ , Masahiro Ishikane ² , Tatsunori Ogawa ³ , Noriko Kinoshita ² , Harutaka Katano ⁴ , Tadaki Suzuki ⁴ , Takashi Fukaya ³ , Fumihiko Hinoshita ⁵ , Norio Ohmagari ²



Affiliations

• PMID: 32526746
• DOI: 10.1159/000508062

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) is a global health threat. It is a respiratory disease, and acute kidney injury (AKI) is rare; however, if a patient develops severe AKI, renal replacement therapy (RRT) should be considered. Recently, we had a critically ill COVID-19 patient who developed severe AKI and needed continuous RRT (CRRT). To avoid the potential risk of infection from CRRT effluents, we measured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic material in the effluents by qRT-PCR, and low copy numbers of the viral genome were detected. Due to unstable hemodynamic status in critically ill patients, CRRT should be the first choice for severe AKI in COVID-19 patients. We suggest prevention of clinical infection and control during administration of RRT in the acute phase of COVID-19 patients with AKI or multiple organ failure.

Keywords: Acute kidney injury; COVID-19; Continuous renal replacement therapy.